# Chlorpromazine

```text
DRUG INFORMATION

  ADULT
    - Some patients require higher dosages (e.g., 800 mg daily is not uncommon in
      discharged mental patients).
      Source: US FDA label for chlorpromazine (Chlorpromazine Hydrochloride), section
      'dosage and administration', retrieved 2026-08-29
    - Usually patient becomes quiet and cooperative within 24 to 48 hours and oral doses
      may be substituted and increased until the patient is calm. 500 mg a day is
      generally sufficient.
      Source: US FDA label for chlorpromazine (Chlorpromazine Hydrochloride), section
      'dosage and administration', retrieved 2026-08-29
    - While gradual increases to 2,000 mg a day or more may be necessary, there is
      usually little therapeutic gain to be achieved by exceeding 1,000 mg a day for
      extended periods.
      Source: US FDA label for chlorpromazine (Chlorpromazine Hydrochloride), section
      'dosage and administration', retrieved 2026-08-29

  CHILD
    - – PEDIATRIC PATIENTS (6 MONTHS TO 12 YEARS OF AGE) Chlorpromazine hydrochloride
      should generally not be used in pediatric patients under 6 months of age except
      where potentially lifesaving. It should not be used in conditions for which
      specific pediatric dosages have not been established. Severe Behavioral Problems
      Outpatients Select route of administration according to severity of patient's
      condition and increase dosage gradually as required.
      Source: US FDA label for chlorpromazine (Chlorpromazine Hydrochloride), section
      'dosage and administration', retrieved 2026-08-29
    - In severe behavior disorders, higher dosages (50 to 100 mg daily, and in older
      children, 200 mg daily or more) may be necessary.
      Source: US FDA label for chlorpromazine (Chlorpromazine Hydrochloride), section
      'dosage and administration', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - No kidney-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for chlorpromazine (Chlorpromazine
      Hydrochloride), retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - No liver-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for chlorpromazine (Chlorpromazine
      Hydrochloride), retrieved 2026-08-29

  PREGNANCY
    - Usage in Pregnancy Safety for the use of chlorpromazine hydrochloride during
      pregnancy has not been established.
      Source: US FDA label for chlorpromazine (Chlorpromazine Hydrochloride), section
      'pregnancy', retrieved 2026-08-29
    - Therefore, it is not recommended that the drug be given to pregnant patients
      except when, in the judgment of the physician, it is essential.
      Source: US FDA label for chlorpromazine (Chlorpromazine Hydrochloride), section
      'pregnancy', retrieved 2026-08-29
    - The potential benefits should clearly outweigh possible hazards.
      Source: US FDA label for chlorpromazine (Chlorpromazine Hydrochloride), section
      'pregnancy', retrieved 2026-08-29

  BREASTFEEDING
    - There is evidence that chlorpromazine hydrochloride is excreted in the breast milk
      of nursing mothers.
      Source: US FDA label for chlorpromazine (Chlorpromazine Hydrochloride), section
      'nursing mothers', retrieved 2026-08-29
    - Because of the potential for serious adverse reactions in nursing infants from
      chlorpromazine hydrochloride, a decision should be made whether to discontinue
      nursing or to discontinue the drug, taking into account the importance of the drug
      to the mother.
      Source: US FDA label for chlorpromazine (Chlorpromazine Hydrochloride), section
      'nursing mothers', retrieved 2026-08-29
```

---

Dawaa Reference is a reference for prescribers, not a medical device, and does not replace clinical judgement.

[Privacy policy](/privacy)